Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial

Frontiers in Oncology

Oncology

Chang Wang¹  Tingting Liang¹  Yu Han²  Yuxian Bai²  Li Man³  Xin Wang⁴  Lijie He⁵  Chuanchun Leng⁶  Jinglei Qu⁷  Ying Chen⁷  Xiujuan Qu⁷  Xin He⁷  Ying Luo⁷  Yunpeng Liu⁷  Ping Yu⁷  Jing Liu⁸  Caiyun Zhou^1,10 

[1] Cancer Center, The First Hospital of Jilin University, Changchun, China;Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China;Department of Medical Oncology, Anshan Cancer Hospital, Anshan, China;Department of Medical Oncology, General Hospital of Benxi Iron and Steel Industry Group of Liaoning Health Industry Group, Benxi, China;Department of Medical Oncology, People’s Hospital of Liaoning Province, Shenyang, China;Department of Medical Oncology, The Central Hospital of Anshan, Anshan, China;Department of Medical Oncology, The First Hospital of China Medical University, China Medical University, Shenyang, China;Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China;Liaoning Province Clinical Research Center for Cancer, Shenyang, China;Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China;Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China;Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, China;The Fourth Oncology Departments, Huludao Central Hospital, Huludao, China;

关键词: second-line apatinib plus irinotecan;    gastric adenocarcinoma;    gastroesophageal junction adenocarcinoma;    treatment efficacy;    safety;   

DOI  :  10.3389/fonc.2023.1072943

 received in 2022-10-18, accepted in 2023-03-27,  发布年份 2023

来源: Frontiers

【 摘 要 】

ObjectiveApatinib and irinotecan are used as systematic therapies for advanced gastric adenocarcinoma (GAC) and gastroesophageal junction adenocarcinoma (GEJA), while the evidence for their combination as second-line therapy in these patients is limited. This study aimed to evaluate the efficacy and safety of second-line apatinib plus irinotecan for the treatment of GAC and GEJA.MethodsIn this prospective, multicenter phase II clinical study, 28 patients with advanced GAC or GEJA who received second-line apatinib plus irinotecan were recruited.ResultsIn total, 1 (3.6%) patient achieved complete response, 7 (25.0%) patients achieved partial response, 13 (46.4%) patients had stable disease, and 4 (14.3%) patients showed progressive disease, while clinical response was not evaluable or not assessed in 3 (10.7%) patients. The objective response rate and disease control rate were 28.6% and 75.0%, respectively. Meanwhile, the median (95% confidence interval (CI)) progression-free survival (PFS) was 4.5 (3.9-5.1) months, and the median (95% CI) overall survival (OS) was 11.3 (7.4-15.1) months. By multivariate Cox regression analysis, male sex, liver metastasis, and peritoneal metastasis were independently associated with worse PFS or OS, while treatment duration ≥5 months was independently associated with better OS. In terms of the safety profile, 89.3% of patients experienced treatment-emergent adverse events of any grade, among which 82.1% of patients had grade 1-2 adverse events and 64.3% of patients had grade 3-4 adverse events.ConclusionApatinib plus irinotecan as second-line therapy achieves a good treatment response and satisfactory survival with tolerable safety in patients with advanced GAC or GEJA.

【 授权许可】

Unknown   
Copyright © 2023 Qu, He, Luo, Yu, Chen, Liu, Wang, Wang, Liang, Bai, Han, Man, Leng, Zhou, He, Wang, Liu and Qu